HeyJaredMove Science Forward - The Biz with Dr. Kambiz.
Welcome to "Move Science Forward - the Biz with Dr. Kambiz"Join us for a fresh and lively livestream series on LinkedIn where we dive into the world of science and its adjacent fields.
- Indexed episodes, last 90 days
- 3
- Latest publication
- Sep 2, 2026
- Audience
- Checking…
- Earliest in this view
- Aug 9, 2026
Latest episodes
Mat Legut on the BIZ with Dr. Kambiz! (opens the original)
Read excerpt
Dr. Legut is co-founder and CEO of OverT Bio. An immunologist with over a decade of experience in basic and translational oncology, his work spans cell therapy, oncolytic viruses, antigen discovery and nanomedicine. With Dr. Sanjana, he developed the genome-scale overexpression and cell programming platform in immune cells that powers OverT's immunotherapies. Prior to OverT, he helped develop clinical programs for gamma delta T cells, CAR-T cells and TILs, and served as a Hope Fellow at the New
Isaac Stoner on the BIZ with Dr. Kambiz! (opens the original)
Read excerpt
Isaac Stoner, CEO of MindImmune Therapeutics, joins Dr. Kambiz for a straight-talking conversation about what has gone wrong in US biotech and what would actually fix it. Isaac has made the case that the industry has drifted toward me-too and me-better assets. Here he digs into what he thinks the real answer is, investment in early-stage innovation, along with what it takes to build a company like MindImmune. Isaac also runs Boston's Biotech n' Beer Meetup, so we get into why the Kendall Square
Michael Bunsick on the BIZ with Dr. Kambiz! (opens the original)
Read excerpt
Michael Bunsick ( mb9677@princeton.edu ) is a postdoctoral fellow at Princeton University in the lab of Bonnie Bassler. His work focuses on how bacterial viruses exploit a chemical communication process called quorum sensing to optimize their infectious lifecycle. Michael earned both his B.Sc. and Ph.D. from the University of Toronto. Michael is also working on commercializing new DNA assembly and cloning technology he developed during his postdoc. VectorWeave is commercializing a proprietary DN
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about Move Science Forward - The Biz with Dr. Kambiz.